跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AYBINTIO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
AYBINTIO
Authorized
STANDARD
AYBINTIO
Samsung Bioepis Co., Ltd.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
d80199ee759cd832
Company
Samsung Bioepis Co., Ltd.
Type
Standard
Approval Details
Approval Id
d80199ee759cd832
Drug Approval Canada Name
AYBINTIO
Product Name
AYBINTIO
Status
Marketed
Status Date
2022-06-27
Original Market Date
2022-06-27
Din
02522829
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription Recommended , Schedule D
Ahfs
10:00.00
Atc Original
L01FG01 BEVACIZUMAB
Atc Name
l 01 fg 01
Aig Number
0151381001
Company Name
Samsung Bioepis Co., Ltd.
Company Address
76, Songdogyoyuk-Ro, Yeonsu-Gu, Incheon, Incheon, Korea, Republic Of, 21987
Company Detail Path
/organization/samsung-bioepis-co-ltd
Company Information
Pharmaceutical Company Name
Samsung Bioepis Co., Ltd.
Country Name
South Korea
Province Name
Incheon
City Name
incheon,incheon,country_kr
Address
76 Songdogyoyuk-ro, Yeonsu-gu
Website
http://www.samsungbioepis.com
Active Ingredients
BEVACIZUMAB
100 MG / 4 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
d80199ee759cd832
Type
Standard
Back to Health Canada Approvals